Inibace Plus (Cilazapril, Hydrochlorothiazide)

Cilazapril blocks the angiotensin‑converting enzyme, which reduces the production of angiotensin II, a potent vasoconstrictor. Lower angiotensin II levels lead to relaxation of blood vessels, decreased aldosterone secretion, and ultimately a reduction in blood pressure.

The appropriate dose of Inibace Plus is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Inibace Plus is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy. Limited data are available for breastfeeding; therefore, the medication is generally avoided unless the potential benefit justifies the potential risk.

To request Inibace Plus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Inibace Plus offers a dual mechanism by combining an ACE inhibitor with a thiazide diuretic, providing additive blood‑pressure reduction. Compared with monotherapy agents, the combination can achieve better control with a single pill, but individual tolerability and patient comorbidities must be considered when selecting therapy.

Inibace Plus tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources to maintain product stability.

Inibace Plus is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse reactions can include severe hypotension, angioedema (swelling of the face, lips, tongue, or airway), acute renal impairment, and hyperkalaemia. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden loss of blood pressure, or marked changes in kidney function.

Inibace Plus should be avoided in patients with known hypersensitivity to cilazapril, hydrochlorothiazide, or any component of the formulation, in those with a history of angioedema related to ACE inhibitors, and in pregnant women. Caution is also advised for individuals with severe renal impairment or electrolyte disturbances.